Mazdutide Dosage: Doses Studied, Units and Chart
What doses of Mazdutide have been used in published research, how they convert to syringe units, and what is still unknown.
- Doses studied
- 8 studies
- with a stated dose, listed below
- Frequency
- once weekly
- as used in studies
- Half-life
- Not found
- No published half-life found (PubMed search, 2 Oct 2026)
Doses used in published studies
Each dose below is quoted from a study abstract, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.
| Dose | Frequency and route | Study type | Source |
|---|---|---|---|
| 9 mg vs placebo (2:1) | once weekly · subcutaneous · 60 weeks | Human RCTn = 461 | JAMA 2026, PMID 42251595 |
| 3-6 mg, 10 mg or 16 mg vs placebo | once weekly · subcutaneous · 48 weeks | Human RCTn = 179 | The lancet. Diabetes & endocrinology 2026, PMID 42628555 |
| 4 mg or 6 mg vs placebo | once weekly · subcutaneous · 24 weeks, then 24 weeks extended treatment | Human RCTn = 320 | Nature 2026, PMID 41407859 |
| 4 mg or 6 mg mazdutide vs dulaglutide 1.5 mg | once weekly · subcutaneous · 28 weeks | Human RCTn = 731 | Nature 2026, PMID 41407860 |
| 4 mg or 6 mg vs placebo | once weekly · subcutaneous · 48 weeks | Human RCTn = 610 | The New England journal of medicine 2025, PMID 40421736 |
| 3, 4.5 or 6 mg vs dulaglutide 1.5 mg or placebo | once weekly · subcutaneous · 20 weeks | Human RCT | Diabetes care 2024, PMID 37943529 |
| 3, 4.5 or 6 mg vs placebo | once weekly · subcutaneous · 24 weeks | Human RCTn = 248 | Nature communications 2023, PMID 38092790 |
| IBI362 (mazdutide) 3.0, 4.5 or 6.0 mg vs placebo (2:1) | once weekly · subcutaneous · 12 weeks | Human RCT | EClinicalMedicine 2021, PMID 34430840 |
Before anyone considers it
- Mazdutide is investigational and not approved for any use.
- Products sold as research chemicals are not checked by the FDA for identity, purity or dose.
- Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
- People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.
Common questions
Is Mazdutide FDA approved?
No. Mazdutide is investigational (investigational in the us (approved in china)) and not approved for any use.
Sources
- 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
- 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 3Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.JAMA · 2026PMID 42251595Accessed 2 Oct 2026
- 4Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.The lancet. Diabetes & endocrinology · 2026PMID 42628555Accessed 2 Oct 2026
- 5Mazdutide versus placebo in Chinese adults with type 2 diabetes.Nature · 2026PMID 41407859Accessed 2 Oct 2026
- 6Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.Nature · 2026PMID 41407860Accessed 2 Oct 2026
- 7Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.The New England journal of medicine · 2025PMID 40421736Accessed 2 Oct 2026
- 8Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.Diabetes care · 2024PMID 37943529Accessed 2 Oct 2026
- 9A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.Nature communications · 2023PMID 38092790Accessed 2 Oct 2026
- 10IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study.EClinicalMedicine · 2021PMID 34430840Accessed 2 Oct 2026
- 11PubMed search: mazdutide[tiab] OR IBI362[tiab] OR LY3305677[tiab] (53 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: (mazdutide[tiab] OR IBI362[tiab] OR LY3305677[tiab]) AND (randomized[tiab] OR trial[tiab] OR phase[tiab]) (31 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13PubMed search: (mazdutide[tiab] OR IBI362[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (1 result)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
Found an error? Report a correction.